1 completed, 1 enrolling by invitation, 1 unknown. 2 Phase 2, 1 Not applicable, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 1, Enrolling by invitation 1 |
| Not applicable | 1 | Unknown 1 |
| Phase 3 | 1 | Completed 1 |
Follow Atorvastatin 20 Mg Oral Tablet: new trials by email Literature Review of Atorvastatin 20 Mg Oral Tablet trials Research Report on Atorvastatin 20 Mg Oral Tablet
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Atorvastatin and Alkali Therapy in Patients With Autosomal Dominant Polycystic Kidney Disease Atorvastatin 20 Mg Oral Tablet, Sodium Bicarbonate 600 Mg Oral Tablet - Autosomal Dominant Polycystic Kidney Disease, Chronic Kidney Diseases | Phase 2 | Enrolling by invitation | Taipei Medical University Shuang Ho Hospital | 30 | 2023-05-01 | 2023-05-23 |
| Combination Therapies to Reduce Carriage of SARS-Cov-2 and Improve Outcome of COVID-19 in Ivory Coast: a Phase Randomized IIb Trial Lopinavir/Ritonavir 200 MG-50 MG Oral Tablet, Telmisartan 40Mg Oral Tablet, Atorvastatin 20 Mg Oral Tablet - COVID-19, COVID-19 Drug Treatment | Phase 2 / Phase 3 | Completed | ANRS, Emerging Infectious Diseases | 294 | 2020-11-27 | 2024-12-27 |
| How Atorvastatin Affects the Gut Flora and Metabolomics? Atorvastatin 20 Mg Oral Tablet - Atherosclerotic Cardiovascular Disease | Not applicable | Unknown | First Affiliated Hospital Xi'an Jiaotong University | 30 | 2017-11-13 | 2020-01-02 |
Atherosclerosis (1) · COVID-19 (1) · Polycystic Kidney, Autosomal Dominant (1) · Renal Insufficiency, Chronic (1)
ANRS, Emerging Infectious Diseases (1) · First Affiliated Hospital Xi'an Jiaotong University (1) · Taipei Medical University Shuang Ho Hospital (1)
China (1) · Côte d’Ivoire (1) · Taiwan (1)